JEMPERLI
Showing 1 - 6 of 6
Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)
Not yet recruiting
- Adenocarcinoma - GEJ
- Gastric Adenocarcinoma
- (no location specified)
Sep 26, 2023
Tumors, Rectal Trial (Dostarlimab)
Not yet recruiting
- Neoplasms, Rectal
- Dostarlimab
- (no location specified)
Feb 2, 2023
Ovarian Tumors, Endometrial Tumors, Uterine Cervical Tumors Trial (Dostarlimab, Bevacizumab, Doxorubicin)
Not yet recruiting
- Ovarian Neoplasms
- +5 more
- Dostarlimab
- +4 more
- (no location specified)
Sep 3, 2023
Rectal Tumors, Rectal Tumor Malignant Trial in Iowa City (Niraparib, Dostarlimab, Short course radiation)
Recruiting
- Rectal Neoplasms
- Rectal Neoplasm Malignant
- Niraparib
- +2 more
-
Iowa City, IowaHolden Comprehensive Cancer Center at the University of Iowa
Jul 22, 2022
Recurrent Endometrial Serous Adenocarcinoma Trial in Columbus (procedure, biological, drug)
Not yet recruiting
- Recurrent Endometrial Serous Adenocarcinoma
- Biospecimen Collection
- +4 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
May 12, 2023
Colonic Tumors Trial (Dostarlimab, CAPEOX, FOLFOX)
Not yet recruiting
- Colonic Neoplasms
- Dostarlimab
- +2 more
- (no location specified)
May 3, 2023